检索结果-南通市图书馆

在线全文

学校读者我要写书评

暂无评论

深圳海上世界文化艺术中心

建筑实践 2020年第2期3卷 184-191页

作者：无桢文彦长谷川龙友 Yasuko Okuyama Yoshihiko Taira 伊藤圭佐藤和夫 Michael Sypkens Hiromi Kouda Hiroto Kobayashi WANG Yiqing Taishi Kawada 桢综合计划事务所不详 KMDW

2011年,桢综合计画事务所受招商房地产(CMPD)邀请,在深圳海上世界综合体中设计了第一个文化设施,将成为深圳的标志性艺术文化场馆。深圳海洋世界文化艺术中心(SWCAC)由招商蛇口旗下综合创新文化平台"设计互联"运营,其建筑由两部分组成:... 详细信息

2011年,桢综合计画事务所受招商房地产(CMPD)邀请,在深圳海上世界综合体中设计了第一个文化设施,将成为深圳的标志性艺术文化场馆。深圳海洋世界文化艺术中心(SWCAC)由招商蛇口旗下综合创新文化平台"设计互联"运营,其建筑由两部分组成:平台和展亭。平台上覆盖着白色和绿色的花岗岩,内部是博物馆和零售场所。展亭坐落在平台上,其设计考虑了建筑与周边城市、公园和海洋三个元素间的关系。

关键词：文化艺术中心滨水步道海上世界文化广场

Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

在线全文

学校读者我要写书评

暂无评论

中国神经肿瘤杂志 2013年第1期11卷 21-21页

作者： Shibui S Narita Y Mizusawa J Beppu T Ogasawara K Sawamura Y Kobayashi H Nishikawa R Mishima K Muragaki Y Maruyama T Kuratsu J Nakamura H Kochi M Minamida Y Yamaki T Kumabe T Tominaga T Kayama T Sakurada K Nagane M Kobayashi K Nakamura H ito T Yazaki T Sasaki H Tanaka K Takahashi H Asai A Todo T Wakabayashi T Takahashi J Takano S Fujimaki T Sumi M Miyakita Y Nakazato Y Sato A Fukuda H Nomura K Department of Neurosurgery and Neuro-Oncology National Cancer Center Hospital5-1-1 TsukijiChuo-kuTokyo 104-0045Japan

Objectives: Glioblastoma(GBM) is one of the worst cancers in terms of *** therapy consists of resection with concomitant *** to nimustine hydrochloride(ACNU),an alkylating agent,has been linked to methylguanine DNA methyltransferase(MGMT).Daily administration of procarbazine(PCZ) has been reported to decrease MGMT *** study investigated the efficacy of ACNU + PCZ compared to ACNU alone for GBM and anaplastic astrocytoma(AA).Methods: Patients(20-69 years) who had newly diagnosed AA and GBM were randomly assigned to receive radiotherapy with ACNU alone or with ACNU + *** primary endpoint was overall survival(OS).This was designed as a phase Ⅱ/Ⅲ trial with a total sample size of 310 patients and was registered as UMIN-CTR ***: After 111 patients from 19 centers in Japan were enrolled,this study was terminated early because temozolomide was newly approved in *** median OS and median progression-free survival(PFS) with ACNU alone(n = 55) or ACNU + PCZ(n = 56) in the intention-to-treat population were 27.4 and 22.4 months(P = 0.75),and 8.6 and 6.9 months,*** median OS and median PFS of the GBM subgroup treated with ACNU alone(n = 40) or ACNU + PCZ(n = 41) were 19.0 and 19.5 months,and 6.2 and 6.3 months,*** 3/4 hematologic adverse events occurred in more than 40% of patients in both arms,and 27% of patients discontinued treatment because of adverse ***: The addition of PCZ to ACNU was not beneficial,in comparison with ACNU alone,for patients with newly diagnosed AA and GBM.

关键词：星形细胞母细胞随机试验放疗胶质变性化疗 MGMT

胆固醇酯转移蛋白基因的蛋白质截断型变异体与冠状动脉性心脏病风险的关系

在线全文

学校读者我要写书评

暂无评论

中华高血压杂志 2017年第9期25卷 899-899页

作者： Nomura A Won HH Khera AV Takeuchi F ito K McCarthy S Emdin CA Klarin D Natarajan P Zekavat SM Gupta N Peloso GM Borecki IB Teslovich TM Asselta R Duga S Merlini PA Correa A Kessler T Wilson JG Bown MJ Hall AS Braund PS Carey DJ Murray MF Kirchner HL Leader JB Lavage DR Manus JN Hartze DN Samani NJ Schunkert H Marrugat J Elosua R McPherson R Farrall M Watkins H Juang JJ Hsiung CA Lin SY Wang JS Tada H Kawashiri MA Inazu A Yamagishi M Katsuya T Nakashima E Nakatochi M Yamamoto K Yokota M Momozawa Y Rotter JI Lander ES Rader DJ Danesh J Ardissino D Gabriel S Willer CJ Abecasis GR Saleheen D Kubo M Kato N Ida Chen YD Dewey FE Kathiresan S 刘莉叶鹏

随机对照试验结果表明,抑制胆固醇酯转运蛋白（cholesteryl ester transfer protein,CETP）的疗法并不能降低冠状动脉性心脏病（coronary heart disease,CHD）的发生风险。研究失败的可能原因包括靶目标无效、靶目标外小分子的不良反应... 详细信息

随机对照试验结果表明,抑制胆固醇酯转运蛋白（cholesteryl ester transfer protein,CETP）的疗法并不能降低冠状动脉性心脏病（coronary heart disease,CHD）的发生风险。研究失败的可能原因包括靶目标无效、靶目标外小分子的不良反应和随机对照设计因素影响等。在编码药物靶点的基因中具有天然存在的遗传变异,以此为基础,人类研究可以深入了解针对基因产物的治疗的潜在功效和安全性。

关键词：冠状动脉性心脏病胆固醇酯转运蛋白蛋白基因发生风险蛋白质截断变异体随机对照试验 protein

在线全文

学校读者我要写书评

暂无评论

卒中介入治疗培训指南：国际多学会共识文件

国际脑血管病杂志 2017年第5期25卷 396-399页

作者： Lavine SD Cockroft K Hoh B Bambakidis N Khalessi AA Woo H Riina H Siddiqui A Hirsch JA Chong W Rice H Wenderoth J Mitchell P Coulthard A Signh TJ Phatorous C Khangure M Klurfan P ter Brugge K Iancu D Gunnarsson T Pongpech S Rodesch G Soderman M Taylor A Krings T Orbach D Picard L Suh DC Zheng HQ Jansen O Muto M Szikora I Pierot L Brouwer P Gralla J Renowden S Andersson T Fiehler J Turjman F White P Januel AC Spelle L Kulcsar Z Chapot R Biondi A Dima S Taschner C Szajner M Krajina A Sakai N Matsumaru Y Yoshknura S Ezura M Fujinaka T Iihara K Ishii A Higashi T Hirohata M Hyodo A ito Y Kawanishi M Kiyosue H Kobayashi E Kobayashi S Kuwayama N Matsumoto Y Miyachi S Murayama Y Nagata I Nakahara I Nemoto S Niimi Y Oishi H Satomi J Satow T Sugiu K Tanaka M Terada T Yamagami H Diaz O Lylyk P Jayaraman MV Patsalides A Gandhi CD Lee SK Abruzzo T Albani B Ansari SA Arthur AS Baxter BW Bulsara KR Chen M Almandoz JE Fraser JF Heck DV Hetts SW Hussain MS Klucznik RP Leslie-Mawzi TM Mack WJ McTaggart RA Meyers PM Mocco J Prestigiacomo CA Pride GL Rasmussen PA Starke RM Sunenshine PJ Tarr RW Frei DF Pabo M Nogueira RG Zaidat OO Jovin T Linfante I Yavagal D Liebeskind D Novakovic R Pongpech S 许岩孙瑞郭芮兵 From the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Rolling Meadows IL USA American Society of Neuroradiology (ASNR) Oak Brook IL USA Asian Australasian Federation of lnterventional and Therapeutic Neuroradiology (AAFITN) Bali Indonesia Australian and New Zealand Society of Neuroradiobgy-Conjomt Committee for Recognition of Training in Interventional Neuroradiology (CCINR) representing the RANZCR (ANZSNR) ANZAN and NSA Sydney Australia Canadian Interventional Neuro Group (CING) Edmonton AB Canada World Federation of Interventional and Therapeutic Neuroradiology (WFITN) Gold Coast Australia European Society of Neuroradiology (ESNR) Milan Italy European Society of Minimally Invasive Neurologic Therapy (ESMINT) Nice France Japanese Society for Neuroendovascular therapy (JSNET) Okayama Japan Sociedad Ibero Latino Americana de Neuroradiologica (SILAN) Cartagena Colombia Society of Neurolnterventional Surgery (SNIS) Washington DC USA Society of Vascular and Interventional Neurology (SVIN) Brooklyn NY USA 南京大学医学院附属金陵医院(南京军区南京总医院)神经内科 210002 解放军第一0一医院(无锡太湖医院)神经内科无锡214004

1背景缺血性卒中是全球人口死亡和残疾的首要原因。很多急性大血管闭塞（emergent large vesselocclusion，ELVO）患者都会遗留长期残疾。事实上，这些颅内大动脉闭塞经常会导致大面积脑损伤，进而造成患者死亡或严重致残。

关键词：缺血性卒中培训指南介入治疗文件学会国际血管闭塞动脉闭塞

Performance and calibration of quark/gluon-jet taggers using 140 fb^(-1) of pp collisions at √s=13 TeV with the ATLAS detector

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第2期48卷 1-25页

作者： G. Aad B. Abbott K. Abeling N.J. Abicht S.H. Abidi A. Aboulhorma H. Abramowicz H. Abreu Y. Abulaiti B.S. Acharya C. Adam Bourdarios L. Adamczyk S.V. Addepalli M.J. Addison J. Adelman A. Adiguzel T. Adye A.A. Affolder Y. Afik M.N. Agaras J. Agarwala A. Aggarwal C. Agheorghiesei A. Ahmad F. Ahmadov W.S. Ahmed S. Ahuja X. Ai G. Aielli A. Aikot M. Ait Tamlihat B. Aitbenchikh I. Aizenberg M. Akbiyik T.P.A. Åkesson A.V. Akimov D. Akiyama N.N. Akolkar K. Al Khoury G.L. Alberghi J. Albert P. Albicocco G.L. Albouy S. Alderweireldt M. Aleksa I.N. Aleksandrov C. Alexa T. Alexopoulos F. Alfonsi M. Algren M. Alhroob B. Ali H.M.J. Ali S. Ali S.W. Alibocus M. Aliev G. Alimonti W. Alkakhi C. Allaire B.M.M. Allbrooke J.F. Allen C.A. Allendes Flores P.P. Allport A. Aloisio F. Alonso C. Alpigiani M. Alvarez Estevez A. Alvarez Fernandez M. Alves Cardoso M.G. Alviggi M. Aly Y. Amaral Coutinho A. Ambler C. Amelung M. Amerl C.G. Ames D. Amidei S.P. Amor Dos Santos K.R. Amos V. Ananiev C. Anastopoulos T. Andeen J.K. Anders S.Y. Andrean A. Andreazza S. Angelidakis A. Angerami A.V. Anisenkov A. Annovi C. Antel M.T. Anthony E. Antipov M. Antonelli F. Anulli M. Aoki T. Aoki J.A. Aparisi Pozo M.A. Aparo L. Aperio Bella C. Appelt A. Apyan N. Aranzabal S.J. Arbiol Val C. Arcangeletti A.T.H. Arce E. Arena J-F. Arguin S. Argyropoulos J.-H. Arling O. Arnaez H. Arnold G. Artoni H. Asada K. Asai S. Asai N.A. Asbah J. Assahsah K. Assamagan R. Astalos S. Atashi R.J. Atkin M. Atkinson H. Atmani P.A. Atmasiddha K. Augsten S. Auricchio A.D. Auriol V.A. Austrup G. Avolio K. Axiotis G. Azuelos D. Babal H. Bachacou K. Bachas A. Bachiu F. Backman A. Badea P. Bagnaia M. Bahmani A.J. Bailey V.R. Bailey J.T. Baines L. Baines O.K. Baker E. Bakos D. Bakshi Gupta V. Balakrishnan R. Balasubramanian E.M. Baldin P. Balek E. Ballabene F. Balli L.M. Baltes W.K. Balunas J. Balz E. Banas M. Bandieramonte A. Bandyopadhyay S. Bansal L. Barak M. Barakat E.L. Barberio D. Barberis M. Barbero M.Z. Barel K.N. Barends T. Barillari M-S. Barisits T. Barklow P. Baron D.A. Baron Mo The ATLAS Collaboration

The identification of jets originating from quarks and gluons,often referred to as quark/gluon tagging,plays an important role in various analyses performed at the Large Hadron Collider,as Standard Model measurements and searches for new particles decaying to quarks often rely on suppressing a large gluon-induced *** paper describes the measurement of the efficiencies of quark/gluon taggers developed within the ATLAS Collaboration,using √s=13 TeV proton–proton collision data with an integrated luminosity of 140 fb^(-1) collected by the ATLAS *** taggers with high performances in rejecting jets from gluon over jets from quarks are studied:one tagger is based on requirements on the number of inner-detector tracks associated with the jet,and the other combines several jet substructure observables using a boosted decision tree.A method is established to determine the quark/gluon fraction in data,by using quark/gluon-enriched subsamples defined by the jet *** in tagging efficiency between data and simulation are provided for jets with transverse momentum between 500 GeV and 2 TeV and for multiple tagger working points.

关键词： ATLAS JET QUARK GLUON TAGGING